GW Pharmaceuticals Announces Date and Time Change for Q4 and Year-End 2015 Financial Results and Conference Call

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Nov 30, 2015

- Change to after market on 7 December to facilitate inclusion of additional Epidiolex data -

London, UK, 30 Nov 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces that it has changed the date and time for the release of its fourth quarter and year end results and associated conference call to facilitate inclusion of newly available data from the physician-led Epidiolex® expanded access program.

The new date and time for GW’s fourth quarter and year-end financial results for the period ending 30 September will be Monday 7 December, 2015 at 4:00 p.m. EST (9:00 p.m GMT).

GW will also host a conference call the same day at 4:30 p.m. EST (9:30 p.m. GMT). Conference call information will be provided in the financial results press release issued after the US market close that day. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc

(Today)  +44 20 3727 1000

Stephen Schultz, VP Investor Relations (U.S.)

917 280 2424 / 401 500 6570

FTI Consulting (Media Enquiries)

 

Ben Atwell / Simon Conway

+ 44 20 3727 1000

Recent News